gastric mucosa-associated lymphoid tissue lymphoma
gastric mucosa-associated lymphoid tissue lymphoma
Explore linked clinical trials. Standard reference: MONDO:00062265 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma | gastric mucosa-associated lymphoid tissue lymphoma | Active, not recruiting | Early phase 1 | 2026-10-06 | NCT03680586 | |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, gastric mucosa-associated lymphoid tissue lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma | Recruiting | Phase 2 | 2026-09-29 | NCT07583810 | |
| Cohort Study for Gastric MALT Lymphoma | gastric mucosa-associated lymphoid tissue lymphoma | Recruiting | Not stated | 2026-09-28 | NCT06454149 | |
| Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, gastric mucosa-associated lymphoid tissue lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2025-08-27 | NCT07144657 | |
| Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | gastric mucosa-associated lymphoid tissue lymphoma | Recruiting | Phase 2 | 2024-02-23 | NCT06228963 |